Evidence map›Paper›PMID 38579728›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2024

Hit-and-run epigenome editing durably lowers cholesterol in mice.

Renzhi Han

Abstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Renzhi HanDepartment of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Electronic address: rh11@iu.edu.

Funding

Molecular and cellular functions of Ano5 in heartR01HL116546 · NHLBI · OHIO STATE UNIVERSITY · PI HAN, RENZHI · 2013 to 2022
$4.4M
Development of gene editing based therapy for cardiovascular diseasesR01HL159900 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHEN, YUQING EUGENE, HAN, RENZHI · 2021 to 2024
$2.8M
Controllable base editing therapy for DMDR01HL170260 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI Renzhi Han · 2023 to 2026
$2.4M
Targeted editing of ASGR1 for cardiovascular diseasesR01HL169976 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI YUQING Eugene CHEN, Renzhi Han · 2024 to 2026
$2.1M
Base editing of ASGR1 for cardiovascular diseaseR21HL163720 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI HAN, RENZHI · 2023 to 2024
$436k
NHLBI NIH HHS R01 HL116546NHLBI NIH HHS R01 HL159900NHLBI NIH HHS R01 HL169976NHLBI NIH HHS R01 HL170260NHLBI NIH HHS R21 HL163720
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CholesterolGene EditingAnimalsCRISPR-Cas SystemsDisease Models, AnimalEpigenesis, GeneticEpigenomeHumansMiceCholesterol

Identifiers

PMID38579728
PMCPMC11081912

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.